- Sanofi press release (SNY): Q3 Non-GAAP EPS of €3.55 beats by €2.04.
- Revenue of €14.44B (+16.2% Y/Y) beats by €1.12B.
- Pharma launches sales increased by 31.4%, reaching €1.4 billion, driven by ALTUVIIIO, Ayvakit, and Rezurock.
- Dupixent sales increased by 34.8% to €5.7 billion, above €5 billion per quarter
Sanofi beats top-line and bottom-line estimates; raises FY26 outlook
